US Capitol Capsule: Ebola crisis spurs vows to boost global health security

With West Africa's hospitals and treatment centers overwhelmed and its health systems near collapse – leaving people to die in the streets – the Ebola outbreak has spotlighted not only the need to ensure global capacity and systems are in place to better prevent, detect and rapidly respond to biological threats before they become out-of-control epidemics, but to make sure those capabilities are enduring, leaders from 44 countries declared during a 26 September meeting at the White House.

With West Africa's hospitals and treatment centers overwhelmed and its health systems near collapse – leaving people to die in the streets – the Ebola outbreak has spotlighted not only the need to ensure global capacity and systems are in place to better prevent, detect and rapidly respond to biological threats before they become out-of-control epidemics, but to make sure those capabilities are enduring, leaders from 44 countries declared during a 26 September meeting at the White House.

Too often, the world has scrambled to coordinate a response to a disease outbreak, whether it has been the 2002-03...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

Bavarian Nordic Well Placed To Meet Mpox Vaccine Demand

 

The company will ramp up manufacturing of its Jynneos vaccine to meet demand in worst-affected African countries and stockpiling richer nations.  

Cagrisema Leads The Charge For 2025

 

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.